Related Experiment Video
Updated: Sep 13, 2025
Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
Published on: June 10, 2025
Validation and optimization of classification criteria for childhood-onset systemic lupus erythematosus in a
Yudi Zhang1, Tian Shen1, Sihao Gao2
1Department of Pediatrics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Insights
The 2012 SLICC and 2019 EULAR/ACR classification criteria showed good diagnostic accuracy in Chinese childhood-onset Systemic Lupus Erythematosus (cSLE) patients. Optimization of the 2019 criteria improved specificity without reducing sensitivity.
Area of Science:
- Rheumatology
- Pediatric Rheumatology
- Immunology
Background:
- Childhood-onset Systemic Lupus Erythematosus (cSLE) diagnosis relies on classification criteria.
- Existing criteria, such as the 2012 Systemic Lupus International Collaborating Clinics (SLICC) and 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology (EULAR/ACR) criteria, require evaluation for specific populations.
- Tailoring classification criteria can improve diagnostic accuracy in diverse ethnic groups.
Purpose of the Study:
- To assess the diagnostic performance of the 2012 SLICC and 2019 EULAR/ACR criteria in Chinese cSLE patients.
- To develop an optimized classification schema for cSLE based on the 2019 EULAR/ACR criteria.
Main Methods:
- Retrospective data analysis from the CAPRID database for cSLE and control cases.
- Gold-standard diagnosis established by consensus among 43 rheumatologists.
- Evaluation of 2012 SLICC and 2019 EULAR/ACR criteria in a cohort of 1,045 patients (512 cSLE/533 non-cSLE).
- Optimization of 2019 EULAR/ACR criteria using LASSO regression and expert consultation, followed by validation.
Main Results:
- The 2012 SLICC criteria achieved 96.7% sensitivity and 96.5% specificity.
- The 2019 EULAR/ACR criteria showed 95.3% sensitivity and 97.8% specificity.
- Optimizing the 2019 EULAR/ACR criteria by removing non-scarring alopecia and arthritis, and redefining the urinary protein criterion, significantly improved specificity to 99.3% (P < 0.05) while maintaining sensitivity at 94.1% (P = 0.210).
- The optimized scheme enhanced specificity in the ANA-positive subgroup to 97.7% from 86.4% (P = 0.012), with comparable sensitivity.
Conclusions:
- Both 2012 SLICC and 2019 EULAR/ACR criteria demonstrate good diagnostic accuracy in Chinese cSLE patients.
- An optimized version of the 2019 EULAR/ACR criteria, by excluding alopecia and arthritis and modifying the urinary protein criterion, offers improved specificity without compromising sensitivity.
- This refined schema may enhance the classification of cSLE in this population.
Objective:
This study evaluated the diagnostic accuracy of the 2012 SLICC and 2019 EULAR/ACR criteria in Chinese cSLE patients and aimed to develop an optimized classification schema based on the 2019 EULAR/ACR criteria, specifically tailored for cSLE.
Methods:
Data from cSLE and control cases were extracted from the CAPRID database. Gold-standard diagnosis were established by consensus among 43 rheumatologists (≥80% agreement). From 1,390 consensus cases, a random selection of 1,045 cases (512 cSLE/533 non-cSLE) were allocated to derivation (n=522) and validation (n=523) cohorts. The 2012 SLICC and 2019 EULAR/ACR criteria were evaluated in the total cohort. Multiple optimization schemes were then developed through LASSO regression with expert consultation in the derivation cohort. All potential optimization schemes underwent validation in the validation cohort, from which the optimal scheme was selected and further evaluated in an ANA-positive subgroup.
Results:
The 2012 SLICC criteria demonstrated sensitivity of 96.7% and specificity of 96.5%, while the 2019 EULAR/ACR criteria had sensitivity of 95.3% and specificity of 97.8%, with an optimal total score threshold of 10. When both the non-scarring alopecia and arthritis criteria were removed alongside the redefined urinary protein criterion, specificity significantly improved to 99.3% (P < 0.05), while sensitivity remained unaffected at 94.1% (P = 0.210). In the ANA-positive cohort, the optimized integrated scheme significantly improved specificity (97.7% vs. 86.4%, P = 0.012) while maintaining comparable sensitivity (96.2% vs. 97.8%, P = 0.138).
Conclusion:
Both criteria performed well in Chinese cSLE patients. Optimizing the 2019 EULAR/ACR criteria by removing alopecia and arthritis criteria and modifying the urinary protein criterion enhanced specificity without compromising sensitivity.
